Correction to Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study

IF 7.6 2区医学 Q1 HEMATOLOGY

HemaSphere Pub Date : 2025-05-14 DOI:10.1002/hem3.70142

引用次数: 0

Abstract

Morè S, Federici I, Bossi A, et al. Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: results from the prospective, observational CHAGAL study. HemaSphere. 2025;9:e70079. https://doi.org/10.1002/hem3.70079

In the author listing of the manuscript, the name of an author was incorrectly listed as Tommaso C. De Toritto. The correct name is Tommaso Caravita di Toritto.

Additionally, the author listing requires further amendment due to an error in the initial manuscript draft. As such, Angela Rago is now included as a co-author.

The original article has been updated. We apologize for this error.

查看原文本刊更多论文

修正阴烧或多发性骨髓瘤患者中I型戈谢病的患病率：来自前瞻性观察性CHAGAL研究的结果

Morè S, Federici I, Bossi A，等。阴燃或多发性骨髓瘤患者中I型戈谢病的患病率：来自前瞻性观察性CHAGAL研究的结果HemaSphere。2025; 9: e70079。https://doi.org/10.1002/hem3.70079In手稿的作者名单，一个作者的名字被错误地列为托马索·c·德·托里托。正确的名字是托马索·卡拉维塔·迪·托里托。此外，由于初稿中的错误，作者列表需要进一步修改。因此，安吉拉·拉戈现在被列为作者之一。原文已更新。我们为这个错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HemaSphere Medicine-Hematology

CiteScore

6.10

自引率

4.50%

发文量

2776

审稿时长

7 weeks

期刊介绍： HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.